*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: NanoViricides, Inc. (NYSE American: NNVC)
NNVC is our new NYSE breakout opportunity.
This has been a very big winner for you many times now following our alerts.
We think it presents another compelling opportunity, as it did before.
Following our previous alert, the company rallied +53% in 2 months.
Before that, in January, NNVC rallied +35% in about a month.
Now, NNVC could be positioning for another big move higher.
A breakout and close above Friday's highs could present increased upside potential.
NNVC is a NYSE listed "clinical stage company that is creating special purpose nanomaterials for antiviral therapy".
The Company's "novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc".
NNVC's "lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections".
- "NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection."
An "estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum".
As the company further explains:
"NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs."
Importantly:
- "NV-387 is expected to become an "emperic therapy" for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections."
- "NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy."
Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection.
This has "tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection".
The Company is "currently focused on advancing NV-387 into Phase II human clinical trials".
The Company is also "developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others".
NanoViricides' "platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel."
NNVC "holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses."
Most recently, the company announced:
"NanoViricides Measles Drug Development Animal Study is Imminent"
Here are some of the company's comments from this press release:
"NV-387 actually cured lethal RSV infection in animals, and Measles is a cousin of RSV," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding, "This gives us confidence that NV-387 will have strong activity against Measles virus as well."
As the company further explains:
"There is no approved drug for the treatment of Measles virus infection."
Recently, CDC included Vitamin A as part of the standard of care for Measles infection. Vitamin A is known to help malnourished children with Measles, but its role as supplementary addition to non-deficient patients is not known. CDC also recommended use of ribavirin in extreme cases as a last resort. Ribavirin is a toxic nucleoside analog and is not approved for treatment of Measles."
In addition, the company also announced:
- "With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan"
NNVC could be in a position to experience increased growth.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
Tidak ada komentar:
Posting Komentar